163 related articles for article (PubMed ID: 38103099)
1. Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
Support Care Cancer; 2023 Dec; 32(1):35. PubMed ID: 38103099
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
J Thromb Thrombolysis; 2023 Jul; 56(1):147-155. PubMed ID: 37133703
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
4. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study.
Leclerc V; Karlin L; Herledan C; Marchal L; Baudouin A; Gouraud A; Caffin AG; Larbre V; Lazareth A; Bachy E; Salles G; Ghesquières H; Rioufol C; Ranchon F
J Cancer Res Clin Oncol; 2022 Apr; 148(4):975-984. PubMed ID: 34143239
[TBL] [Abstract][Full Text] [Related]
6. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
[TBL] [Abstract][Full Text] [Related]
7. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population.
Crowley MP; Eustace JA; O'Shea SI; Gilligan OM
Clin Appl Thromb Hemost; 2014 Sep; 20(6):600-6. PubMed ID: 24486624
[TBL] [Abstract][Full Text] [Related]
9. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
[TBL] [Abstract][Full Text] [Related]
10. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
[TBL] [Abstract][Full Text] [Related]
11. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N
Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516
[TBL] [Abstract][Full Text] [Related]
12. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
Li Q; Zhang B; Cheng Q; Zhao F; Li J; Yan H; Xu A; Sun C; Hu Y
Ann Med; 2023; 55(2):2263019. PubMed ID: 37983471
[TBL] [Abstract][Full Text] [Related]
13. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study.
Bao L; Fang LJ; Xiao MY; Lu MQ; Chu B; Shi L; Gao S; Xiang QQ; Wang YT; Liu X; Ding YH; Xin Z; Chen Y; Wang MZ; Hu WK; Guo CY; Chen LY; Sun K
Thromb Res; 2024 Apr; 236():130-135. PubMed ID: 38430904
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
15. [Risk Factors of Multiple Myeloma Complicated with Venous Thromboembolism].
Zhao BN; Dong CX; Kang JM; Ge XY; Zhang JH; Wang MF; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1100-1107. PubMed ID: 37551483
[TBL] [Abstract][Full Text] [Related]
16. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
[TBL] [Abstract][Full Text] [Related]
17. Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma.
Baz R; Furman R; Simondsen K; Stone C
Cancer Control; 2020; 27(2):1073274820930204. PubMed ID: 32551873
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
[TBL] [Abstract][Full Text] [Related]
19. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
